Search Results - "Sibel, Blau"

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer by Hortobagyi, Gabriel N, Stemmer, Salomon M, Burris, Howard A, Yap, Yoon-Sim, Sonke, Gabe S, Paluch-Shimon, Shani, Campone, Mario, Blackwell, Kimberly L, André, Fabrice, Winer, Eric P, Janni, Wolfgang, Verma, Sunil, Conte, Pierfranco, Arteaga, Carlos L, Cameron, David A, Petrakova, Katarina, Hart, Lowell L, Villanueva, Cristian, Chan, Arlene, Jakobsen, Erik, Nusch, Arnd, Burdaeva, Olga, Grischke, Eva-Maria, Alba, Emilio, Wist, Erik, Marschner, Norbert, Favret, Anne M, Yardley, Denise, Bachelot, Thomas, Tseng, Ling-Ming, Blau, Sibel, Xuan, Fengjuan, Souami, Farida, Miller, Michelle, Germa, Caroline, Hirawat, Samit, O’Shaughnessy, Joyce

“…In patients with advanced HR-positive, HER2-negative breast cancer, the addition of the cyclin-dependent kinase inhibitor ribociclib to letrozole was…”
Get full text

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA by Lanman, Richard B, Mortimer, Stefanie A, Zill, Oliver A, Sebisanovic, Dragan, Lopez, Rene, Blau, Sibel, Collisson, Eric A, Divers, Stephen G, Hoon, Dave S B, Kopetz, E Scott, Lee, Jeeyun, Nikolinakos, Petros G, Baca, Arthur M, Kermani, Bahram G, Eltoukhy, Helmy, Talasaz, AmirAli

“…Next-generation sequencing of cell-free circulating solid tumor DNA addresses two challenges in contemporary cancer care. First this method of massively…”
Get full text

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer by Dent, Rebecca, Oliveira, Mafalda, Isakoff, Steven J., Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R., Saura, Cristina, Wongchenko, Matthew J., Xu, Na, Bradley, Denise, Reilly, Sarah-Jayne, Mani, Aruna, Kim, Sung-Bae

“…Purpose In LOTUS (NCT02162719), adding the oral AKT inhibitor ipatasertib to first-line paclitaxel for locally advanced/metastatic triple-negative breast…”
Get full text

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease by Schmid, Peter, Cortes, Javier, Joaquim, Ana, Jañez, Noelia Martínez, Morales, Serafín, Díaz-Redondo, Tamara, Blau, Sibel, Neven, Patrick, Lemieux, Julie, García-Sáenz, José Ángel, Hart, Lowell, Biyukov, Tsvetan, Baktash, Navid, Massey, Dan, Burris, 3rd, Howard A, Rugo, Hope S

“…Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by…”
Get full text

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC) by Dent, Rebecca, Im, Seock-Ah, Espie, Marc, Blau, Sibel, Tan, Antoinette R., Isakoff, Steven J., Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew, Kapp, Amy V., Chan, Wai Y., Singel, Stina M., Maslyar, Daniel J., Baselga, Jose, Kim, Sung-Bae

“…Abstract only…”
Get full text

Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies by Liu, Jie, Halloran, John T., Bilmes, Jeffrey A., Daza, Riza M., Lee, Choli, Mahen, Elisabeth M., Prunkard, Donna, Song, Chaozhong, Blau, Sibel, Dorschner, Michael O., Gadi, Vijayakrishna K., Shendure, Jay, Blau, C. Anthony, Noble, William S.

“…A comprehensive characterization of tumor genetic heterogeneity is critical for understanding how cancers evolve and escape treatment. Although many algorithms…”
Get full text

A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients by Dranitsaris, George, Moezi, Mehdi, Dobson, Kate, Phelan, Robert, Blau, Sibel

“…Background Three different injectable neurokinin-1 (NK-1) receptor antagonist formulations (CINVANTI® [C] vs. intravenous Emend® [E] vs. generic formulations…”
Get full text

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial by Di Leo, Angelo, Johnston, Stephen, Lee, Keun Seok, Ciruelos, Eva, Lønning, Per E, Janni, Wolfgang, O'Regan, Ruth, Mouret-Reynier, Marie-Ange, Kalev, Dimitar, Egle, Daniel, Csőszi, Tibor, Bordonaro, Roberto, Decker, Thomas, Tjan-Heijnen, Vivianne C G, Blau, Sibel, Schirone, Alessio, Weber, Denis, El-Hashimy, Mona, Dharan, Bharani, Sellami, Dalila, Bachelot, Thomas

“…Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit…”
Get full text

Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy by Kolodziej, Michael A., Kwiatkowsky, Lavi, Travis, Patrick M., Blau, Sibel, Kuthiala, Sejal, Telivala, Bijoy Pankaj, Calkins, Geoffrey, Parrinello, Christina

“…e18810 Background: PD1/PDL1 (IO) therapy has been extensively studied as monotherapy and in combination with other IO therapy, chemotherapy and targeted…”
Get full text

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR + /HER2 - Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) by Bardia, Aditya, Hurvitz, Sara A, DeMichele, Angela, Clark, Amy S, Zelnak, Amelia, Yardley, Denise A, Karuturi, Meghan, Sanft, Tara, Blau, Sibel, Hart, Lowell, Ma, Cynthia, Rugo, Hope S, Purkayastha, Das, Moulder, Stacy

“…Standard-of-care treatment for metastatic hormone receptor-positive (HR ), HER2-negative (HER2 ) breast cancer includes endocrine therapy (ET) combined with a…”
Get full text

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial by Kim, Sung-Bae, Dent, Rebecca, Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R, Isakoff, Steven J, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew J, Kapp, Amy V, Chan, Wai Y, Singel, Stina M, Maslyar, Daniel J, Baselga, José, Kim, Sung-Bae, Lee, Keun Seok, Im, Seock-Ah, Espié, Marc, Wang, Hwei-Chung, Blau, Sibel, Dent, Rebecca, Tan, Antoinette, Sohn, Joo Hyuk, De Laurentiis, Michelino, Estevez, Laura Garcia, Huang, Chiun-Sheng, Romieu, Gilles, Velez, Michel, Villanueva, Rafael, Conte, Pier Franco, Dakhil, Shaker, Debled, Marc, Martin, Antonio Gonzalez, Hurvitz, Sara, Kim, Jee Hyun, Levy, Christelle, Oliveira, Mafalda, Rovira, Pedro Sanchez, Seo, Jae Hong, Valero, Vicente, Vidal, Gregory, Wong, Andrea, Allison, Mary Ann K, Figlin, Robert, Chan, David, Chen, Shin-Cheh, Chen, Yen-Hsun, Cobleigh, Melody, De Braud, Filippo, Dirix, Luc, Hansen, Vincent, Bessard, Anne Hardy, Iannotti, Nicholas, Isakoff, Steven, Lawler, William, Montaño, Alvaro, Salkini, Mohamad, Seigel, Leonard

“…The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast…”
Get full text

ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization by Kolodziej, Michael A., Kwiatkowsky, Lavi, Parrinello, Christina, Thurow, Tracy, Schaefer, Eric S., Beck, J. Thaddeus, Cherny, Nathan, Blau, Sibel

“…1508 Background: We have previously reported on the successful implementation of an electronic patient-reported outcomes (ePRO)-based symptom monitoring tool…”
Get full text

Impact of an augmented intelligence-based tool upon the timeliness of referrals to palliative care and hospice in patients with advanced cancer in the real-world setting by Gajra, Ajeet, Jeune-Smith, Yolaine, Balanean, Alexandrina, Ellis, Amy R., Miller, Kelly A., Showalter, John, Bergman, Danielle, Blau, Sibel

“…12127 Background: Timely integration of palliative care (PC) and hospice management for patients with advanced cancer requires informed clinical…”
Get full text

Impact of augmented intelligence (AI) on identification and management of depression in oncology by Frownfelter, John, Blau, Sibel, Zettler, Marjorie, Miller, Kelly, Kish, Jonathan, Valley, Amy W., Gajra, Ajeet

“…Abstract only e14059 Background: Depression is common in patients with cancer and is associated with worse cancer treatment outcomes. Depression is often…”
Get full text

Impact of augmented intelligence (AI) on utilization of palliative care (PC) services in oncology by Gajra, Ajeet, Zettler, Marjorie, Kish, Jonathan, Miller, Kelly, Frownfelter, John, Valley, Amy W., Blau, Sibel

“…Abstract only 12015 Background: Timely integration of palliative care in the management of patients with advanced cancer is a quality benchmark in oncology…”
Get full text

Outcomes among patients with cancer previously identified as being at risk for 30-day mortality using augmented intelligence by Gajra, Ajeet, Zettler, Marjorie E., Ellis, Amy R., Miller, Kelly A., Frownfelter, John G., Valley, Amy W., Blau, Sibel

“…Abstract only 12031 Background: An augmented intelligence (AI) tool using a machine learning algorithm was developed and validated to generate insights into…”
Get full text

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) by Mayer, Ingrid A, Prat, Aleix, Egle, Daniel, Blau, Sibel, Fidalgo, J Alejandro Pérez, Gnant, Michael, Fasching, Peter A, Colleoni, Marco, Wolff, Antonio C, Winer, Eric P, Singer, Christian F, Hurvitz, Sara, Estévez, Laura García, van Dam, Peter A, Kümmel, Sherko, Mundhenke, Christoph, Holmes, Frankie, Babbar, Naveen, Charbonnier, Laure, Diaz-Padilla, Ivan, Vogl, Florian D, Sellami, Dalila, Arteaga, Carlos L

“…Addition of alpelisib to fulvestrant significantly extended progression-free survival in -mutant, hormone receptor-positive (HR ) advanced/metastatic breast…”
Get full text

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care by Pennell, Nathan A, Dillmon, Melissa, Levit, Laura A, Moushey, E Allyn, Alva, Ajjai S, Blau, Sibel, Cannon, Timothy L, Dickson, Natalie R, Diehn, Maximilian, Gonen, Mithat, Gonzalez, Maria Magdalena, Hensold, Jack O, Hinyard, Leslie J, King, Tari, Lindsey, Stacie C, Magnuson, Allison, Marron, Jonathan, McAneny, Barbara L, McDonnell, Theresa M, Mileham, Kathryn Finch, Nasso, Shelley Fuld, Nowakowski, Grzegorz S, Oettel, Kurt R, Patel, Manali I, Patt, Debra A, Perlmutter, Jane, Pickard, Todd A, Rodriguez, Gladys, Rosenberg, Abby R, Russo, Barry, Szczepanek, Connie, Smith, Cardinale B, Srivastava, Piyush, Teplinsky, Eleonora, Thota, Ramya, Traina, Tiffany A, Zon, Robin, Bourbeau, Brian, Bruinooge, Suanna S, Foster, Shelagh, Grubbs, Stephen, Hagerty, Karen, Hurley, Patricia, Kamin, Deborah, Phillips, Jonathan, Schenkel, Caroline, Schilsky, Richard L, Burris, 3rd, Howard A

“…This report presents the American Society of Clinical Oncology's (ASCO's) evaluation of the adaptations in care delivery, research operations, and regulatory…”
Get full text

Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting by Parrinello, Christina, Calkins, Geoffrey, Kwiatkowsky, Lavi, Schaefer, Eric S., Beck, J. Thaddeus, Ellis, Amy R., Blau, Sibel, Telivala, Bijoy Pankaj, Kolodziej, Michael A.

“…1528 Background: Earlier and more effective management of cancer-related symptoms and treatment-related toxicities might improve the survival of patients…”
Get full text

High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining by Campton, Daniel E, Ramirez, Arturo B, Nordberg, Joshua J, Drovetto, Nick, Clein, Alisa C, Varshavskaya, Paulina, Friemel, Barry H, Quarre, Steve, Breman, Amy, Dorschner, Michael, Blau, Sibel, Blau, C Anthony, Sabath, Daniel E, Stilwell, Jackie L, Kaldjian, Eric P

“…Circulating tumor cells (CTCs) are malignant cells that have migrated from solid cancers into the blood, where they are typically present in rare numbers…”
Get full text